Table 3.
Proportion of patients achieving ≥ 4-point reductions in SGRQ total score, by baseline characteristics
| Mepolizumab | Placebo | ||
|---|---|---|---|
| ITT population | |||
| Patients with ≥ 4-point reduction in SGRQ total score, n (%) | 335/466 (72) | 256/465 (55) | |
| Odds ratio (mepolizumab/placebo), 95% CI; p-value | 2.17 (1.63, 2.87); p < 0.001 | ||
| Age at asthma onset: < 18 years | |||
| Patients with ≥ 4-point reduction in SGRQ total score, n (%) | 90/130 (69) | 65/122 (53) | |
| Odds ratio (mepolizumab/placebo), 95% CI | 1.95 (1.12, 3.38) | ||
| Age at asthma onset: 18–< 40 years | |||
| Patients with ≥ 4-point reduction in SGRQ total score, n (%) | 123/173 (71) | 96/171 (56) | |
| Odds ratio (mepolizumab/placebo), 95% CI | 2.17 (1.34, 3.51) | ||
| Age at asthma onset: ≥ 40 years | |||
| Patients with ≥ 4-point reduction in SGRQ total score, n (%) | 121/162 (75) | 95/172 (55) | |
| Odds ratio (mepolizumab/placebo), 95% CI | 2.80 (1.70, 4.62) | ||
| Lung function: ≤ 60% predicted FEV1 | |||
| Patients with ≥ 4-point reduction in SGRQ total score, n (%) | 171/243 (70) | 132/242 (55) | |
| Odds ratio (mepolizumab/placebo), 95% CI | 2.13 (1.44, 3.16) | ||
| Lung function: > 60–80% predicted FEV1 | |||
| Patients with ≥ 4-point reduction in SGRQ total score, n (%) | 137/177 (77) | 98/176 (56) | |
| Odds ratio (mepolizumab/placebo), 95% CI | 3.03 (1.84, 4.99) | ||
| Lung function: ≥ 80% predicted FEV1 | |||
| Patients with ≥ 4-point reduction in SGRQ total score, n (%) | 27/46 (59) | 26/47 (55) | |
| Odds ratio (mepolizumab/placebo), 95% CI | 2.12 (0.70, 6.48) | ||
CI confidence interval, FEV1 forced expiratory volume in 1 s, ITT intent-to-treat, SGRQ St George’s Respiratory Questionnaire